ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
Spectral AI Inc

Spectral AI Inc (MDAI)

2.18
-0.02
(-0.91%)
마감 04 12월 6:00AM
2.20
0.02
(0.92%)
시간외 거래: 9:38AM

개인 투자자를 위한 전문가급 도구.

주요 통계 및 세부정보

가격
2.20
매수가
2.17
매도가
2.20
거래량
4,217,722
2.07 일간 변동폭 2.37
0.8239 52주 범위 3.7205
market_cap
전일 종가
2.20
개장가
2.21
최근 거래 시간
31
@
2.17
마지막 거래 시간
재정 규모
US$ 9,329,383
VWAP
2.2119
평균 볼륨(3m)
1,630,612
발행 주식
18,588,073
배당수익률
-
주가수익률
-1.94
주당순이익(EPS)
-1.12
매출
18.06M
순이익
-20.85M

Spectral AI Inc 정보

Spectral MD Holdings, Ltd., a predictive analytics company, develops AI algorithms and optical technology in wound care treatment. It offers DeepView wound imaging solution, an AI technology and multispectral imaging system that provides healing assessments for burn wounds and diabetic foot ulcers. ... Spectral MD Holdings, Ltd., a predictive analytics company, develops AI algorithms and optical technology in wound care treatment. It offers DeepView wound imaging solution, an AI technology and multispectral imaging system that provides healing assessments for burn wounds and diabetic foot ulcers. Spectral MD Holdings, Ltd. was incorporated in 2020 and is headquartered in Dallas, Texas. 더 보기

섹터
Surgical,med Instr,apparatus
산업
Surgical,med Instr,apparatus
웹사이트
본부
Wilmington, Delaware, USA
설립됨
-
Spectral AI Inc is listed in the Surgical,med Instr,apparatus sector of the 나스닥 with ticker MDAI. The last closing price for Spectral AI was US$2.20. Over the last year, Spectral AI shares have traded in a share price range of US$ 0.8239 to US$ 3.7205.

Spectral AI currently has 18,588,073 shares in issue. The market capitalisation of Spectral AI is US$40.89 million. Spectral AI has a price to earnings ratio (PE ratio) of -1.94.

MDAI 최신 뉴스

Spectral AI Completes Truthing of Burn Center Images, Initiates Emergency Department Image Review

DALLAS, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on revolutionizing medical diagnostics to...

Spectral AI Announces Repricing of its Public Warrants

DALLAS, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on revolutionizing medical diagnostics to...

Spectral AI Announces DeepView SnapShot® M Moves Forward with Feedback from Brooke Army Medical Center Institute of Surgical Research

DALLAS, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (Spectral AI or the Company), an artificial intelligence (AI) company focused on revolutionizing medical diagnostics to...

Spectral AI Raises Up to $5 Million Financing Strengthening Financial Position for FDA Pathway

DALLAS, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on revolutionizing medical...

Spectral AI Announces 2024 Third Quarter Financial Results

Revenue Rose to $8.2 MillionCompany Reaffirms Timeline for Regulatory Submission to U.S. FDA Q3 2024 Overview Research & Development Revenue Rose 138% to $8.2 MillionLast Patient Out at Burn...

Spectral AI Announces Plan to Spin Off Spectral IP Subsidiary Focused on Intellectual Property Investments and Monetization

DALLAS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (“AI”) company focused on medical diagnostics for faster...

Spectral AI Announces Last Patient Out in U.S. Burn Pivotal Study at Burn Centers

Milestone Achievement Supports Planned FDA Submission of DeepView AI®-Burn in 2025 DALLAS, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”...

Spectral AI Schedules 2024 Third Quarter Financial Results and Conference Call

DALLAS, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and...

Spectral AI, Inc. Announces Return of Founder Dr. J. Michael DiMaio as Chairman of the Board of Directors

DALLAS, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and...

Spectral AI Completes Proof of Concept for Wound Measurement Technology

DALLAS, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and...

기간변동변동 %시가고가저가평균 일일 거래량VWAP
10.5533.33333333331.652.73911.34181949661.68053003CS
40.746.66666666671.52.73911.0143831601.60202815CS
120.8360.58394160581.372.73910.823916306121.5655947CS
260.5734.96932515341.632.73910.82398695781.57811102CS
52-1.17-34.71810089023.373.72050.823910340412.0616955CS
156-5.06-69.6969696977.268.90.823910702822.37083131CS
260-5.06-69.6969696977.268.90.823910702822.37083131CS

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
ZJKZJK Industrial Company Ltd
US$ 17.185
(171.06%)
28.21M
CTNTCheetah Net Supply Chain Service Inc
US$ 4.81
(157.22%)
113.16M
ORISOriental Rise Holdings Ltd
US$ 11.11
(69.10%)
1.47M
JYDJayud Global Logistics Ltd
US$ 1.1299
(68.62%)
10.8M
GWAVGreenwave Technology Solutions Inc
US$ 0.6078
(66.52%)
512.32M
REVBRevelation Biosciences Inc
US$ 0.504151
(-46.93%)
6.08M
OMEXOdyssey Marine Exploration Inc
US$ 0.4201
(-43.63%)
4.88M
RITRReitar Logtech Holdings Ltd
US$ 2.68
(-38.39%)
1.25M
XCURExicure Inc
US$ 14.05
(-37.00%)
433.62k
AGFYAgrify Corporation
US$ 32.72
(-36.69%)
285.46k
GWAVGreenwave Technology Solutions Inc
US$ 0.6078
(66.52%)
512.26M
SMCISuper Micro Computer Inc
US$ 40.21
(-4.26%)
200.61M
NVDANVIDIA Corporation
US$ 140.26
(1.18%)
162.81M
INTCIntel Corporation
US$ 22.47
(-6.10%)
135.91M
CHRSCoherus BioSciences Inc
US$ 1.7001
(24.09%)
113.52M

MDAI Discussion

게시물 보기
glenn1919 glenn1919 1 일 전
MDAI..................................https://stockcharts.com/h-sc/ui?s=MDAI&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 7 일 전
MDAI..........................https://stockcharts.com/h-sc/ui?s=MDAI&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 1 주 전
MDAI....................................https://stockcharts.com/h-sc/ui?s=MDAI&p=W&b=5&g=0&id=p86431144783
👍️0
Woodpecker3 Woodpecker3 1 주 전
$MDAI risk of being delisted explains manipulative pump .

The Company is not currently in compliance with the continued listing requirements for The Nasdaq Stock Market. If the Company does not regain compliance and continueto meet the continued listing requirements, the Common Stock may be delisted, which could affect the market price and liquidity for theCompany’s Common Stock and reduce the Company’s ability to raise additional capital. On June 3, 2024, the Company receiveda letter from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC (“Nasdaq”) that the Company was not in compliancewith the requirement of Rule 5550(b)(2) relating to the maintenance of a minimum market value of its listed securities of $35.0 millionfor the last 31 consecutive business days. Pursuant to Nasdaq Listing Rule 5810(c)(3)(C), the Company has 180 calendar days from receiptof a notice from Nasdaq (the “Compliance Period”), to regain compliance with the market value of listed securities requirement.If at any time before December 2, 2024, the closing market capitalization of the Company’s Common Stock closes at or above $35.0million for a minimum of 10 consecutive business days, subject to Nasdaq’s discretion to extend this period pursuant to Nasdaq ListingRule 5810(c)(3)(G) to 20 consecutive business days, Nasdaq will provide written notification that the Company has achieved compliancewith the minimum market capitalization requirement, and the matter would be resolved. If the Company does not regain compliance duringthe review period ending December 2, 2024, then Nasdaq may grant the Company a second 180 calendar day period to regain compliance, providedthe Company meets the continued listing requirement for all other initial listing standards for the Nasdaq, other than the minimum market value of listed securities requirement, and notifies Nasdaq of its intent to cure the deficiency.

Although alternative public and private transaction structures may be available, these may require additional time and cost, may impose operational restrictions onthe Company, and may not be available on attractive terms. The Company’s inability to continue to raise capital with its CommonStock as listed on Nasdaq will harm its business, financial condition and results of operations, and will likely cause the Company’sstock value to further decline.
👍️0
tw0122 tw0122 1 월 전
MDAI watchlist 
👍 1
2248 2248 1 월 전
Making a nice move up today !!
👍️0
Afterhoursearnings3 Afterhoursearnings3 2 월 전
The company will end up being worth a lot more than a 40 cent pump. Loading to hold here
👍 1
tw0122 tw0122 2 월 전
$1.40 Return of founder worth a .40 cent pump

pectral AI, Inc. Announces Return of Founder Dr. J. Michael DiMaio as Chairman of the Board of Directors

Source: GlobeNewswire Inc.

Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that the Company's Founder, Dr. J. Michael DiMaio, has been named Chairman of the Board of Directors.
“Our Board of Directors welcomes Dr. DiMaio back to the role of Spectral AI's Chairman. Given our needs for the future, the Board concluded it was clear Dr. DiMaio’s expertise, leadership style, and deep understanding of our industry and the DeepView® System, paired with his deep commitment to patient care and our employees, make him the right person to lead Spectral AI’s next stage of growth,” said Richard Cotton, current Chairman of the Company’s Board of Directors. “I look forward to supporting him and the rest of the Board as they seize the opportunities ahead.” Mr. Cotton will remain on the Board and serve as the head of the Company’s Audit Committee and Lead Independent Director.
👍️0
tw0122 tw0122 2 월 전
Pump me
👍️0
glenn1919 glenn1919 2 월 전
MDAI...............................https://stockcharts.com/h-sc/ui?s=MDAI&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 2 월 전
MDAI new 52 week low
👍️0
Monksdream Monksdream 3 월 전
MDAI new 52 week low
👍️0
ADVFN_chriscain ADVFN_chriscain 3 월 전
The global market potential for Spectral AI’s Deep View system and MSI technology is vast, spanning multiple high-growth sectors including medical diagnostics, digital health, wound care, military applications, and cosmetics. Assuming clinical validation, this technology could achieve wide-scale adoption within a decade, driven by its versatility, accuracy, non-invasiveness, and ability to integrate with AI for personalized treatment plans. With the development of lower-cost, handheld devices, the market reach could expand dramatically, bringing MSI technology to a global audience across both clinical and consumer sectors.
👍️0
Monksdream Monksdream 3 월 전
MDAI new 52 week low
👍️0
Stockminder Stockminder 5 월 전
"Spectral AI Supports Naked Short Selling Inquiry
June 24 2024 - 8:00AM

Alert
Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has provided support to Nasdaq and the state securities authorities in Florida, Louisiana and Texas to bring to their attention potential market manipulation of the Company’s common stock, primarily in the form of naked short selling.
This inquiry is being led by Erich Spangenberg, a member of the Board of Directors and the Company’s largest shareholder.

Naked short selling is a practice in which shares are sold without first being borrowed or ensuring that they can be borrowed. This creates an artificial selling pressure and allows traders to artificially drive down prices at the expense of retail investors. The practice is generally illegal pursuant to Securities and Exchange Commission (“SEC”) Regulation SHO.

“As detailed in the Company’s SEC filing today, a simple examination of our shareholder lists we obtained from reliable authorities clearly shows that our public float has been artificially increased by over 40% as a result of what I believe is illegal naked shorting,” said Mr. Spangenberg. “We recognize and appreciate Nasdaq’s commitment to ensuring market transparency and integrity, and its mission to protect the interests of investors. It is in this spirit that we look forward to collaborating with all relevant authorities to address instances of potentially illegal naked short selling in our stock, strengthen compliance, and protect our investors.” ...
https://ih.advfn.com/p.php?pid=nmona&article=94090454
👍️0
Monksdream Monksdream 6 월 전
MDAI under $2
👍️0
Afterhoursearnings3 Afterhoursearnings3 6 월 전
Funny that the tape here is always on the low side of the spread and different than Fidelity and Schwab.
👍️0
Afterhoursearnings3 Afterhoursearnings3 6 월 전
Looks to be joining the Russel micro cap index
👍️0
Afterhoursearnings3 Afterhoursearnings3 6 월 전
Oof then busted right through
👍️0
Afterhoursearnings3 Afterhoursearnings3 6 월 전
Strong buying off the 20ema
👍️0
Shoes4289 Shoes4289 7 월 전
So undervalued!!! Insiders were very smart to buy many shares at these levels!
👍️0
Shoes4289 Shoes4289 7 월 전
$MDAI when least expected this stock will explode! Not like an AMC or GME but on real fundamentals. It wont look back. To many reasons to get into in this forum so do your DD and you should figure out why. Just yesterday huge insider buys! All- time lows.
👍️0
Afterhoursearnings3 Afterhoursearnings3 7 월 전
Clock ticking here some big upside coming
👍️ 1
Monksdream Monksdream 7 월 전
MDAI new 52 lo
👍️0
Monksdream Monksdream 7 월 전
MDAI new 52 week low
👍️0
glenn1919 glenn1919 9 월 전
MDAI......................................................https://stockcharts.com/h-sc/ui?s=MDAI&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 9 월 전
GlobeNewswireMarch 13, 2024
DALLAS, March 13, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2023 on Wednesday, March 27, 2024 after the close of the stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time to discuss the results.
👍️0
tw0122 tw0122 9 월 전
MDAI $3a cash machine $$$$
👍️0
TrendTrade2016 TrendTrade2016 9 월 전
MDAI...READY FOR 3 DOLLA
👍️0
halbroke1 halbroke1 9 월 전
MDAI $$$ Could see $10.00++..Float Crazy Low..
👍️0
TrendTrade2016 TrendTrade2016 9 월 전
TRIM SOME FAT ABOVE 2.82
👍️0
TrendTrade2016 TrendTrade2016 9 월 전
MDAI...BLOWING UP ABOVE THAT 4 HOUR CLOUD!!
👍️0
TrendTrade2016 TrendTrade2016 9 월 전
MDAI..LOOKS LIKE 3 BUCKS COMING
👍️0
TrendTrade2016 TrendTrade2016 9 월 전
MDAI..THERE IS THE 2.82 BREAK
👍️0
TrendTrade2016 TrendTrade2016 9 월 전
LOW FLOAT SO SHE WILL MOVE FAST
👍️0
TrendTrade2016 TrendTrade2016 9 월 전
LEVEL 2 NICE AND CLEAN SO FAR
👍️0
TrendTrade2016 TrendTrade2016 9 월 전
MDAI...START YOUR ENGINES
👍️0
tw0122 tw0122 9 월 전
Spectral AI Announces New US Government Contract to Further Accelerate the Development of the Handheld Version of DeepView™ Wound Imaging System

Source: GlobeNewswire Inc.

Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced a new contract with the Defense Health Agency (DHA) and the US Army Medical Material Development Activity (USAMMDA) that provides significant additional support for the development of the handheld version of DeepView™ Wound Imaging System called DeepView SnapShot® M.
This newly secured contract is valued at over $500,000 and will build on the previous awards from other U.S. Government Agencies focused on advancing the handheld, DeepView Snapshot® M, that bring this total for just the DeepView SnapShot® M to greater than $6 million. The ultimate goal of the contract and this targeted non-dilutive funding is to optimize the functionality and size of the device and to ensure its combat readiness. These optimizations will, in turn, increase the device’s potential for a portable, handheld version for home health care and related invaluable assistance to medical professionals in many settings.

“Spectral AI is proud to partner with DHA and the USAMMDA on this crucial initiative. This award further validates Spectral AI’s technology and the importance of a battlefield burn solution we are focusing on,” stated Pete Carlson, CEO of Spectral AI. “We firmly believe that this collaboration will make a profound impact, as the miniaturization of medical devices is essential for introducing innovative medical care to a wider range of clinical settings and patients. This development reaffirms Spectral AI's dedication to shaping the future of accessible medical care and solidifies its position as a trailblazer in AI-driven healthcare innovation.”

The Company has previously announced other significant non-dilutive financial support from the US Government that with this award announced today, now totals over $250 million, including $150 million awarded in the last six months.

About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView® System. DeepView® is a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of substantially exceeding the current standard of care in the future, DeepView® is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about DeepView®, visit www.spectral-ai.com.
👍️0
Monksdream Monksdream 9 월 전
MDAI 10Q. Due March 12
👍️0
Monksdream Monksdream 9 월 전
MDAI 10Q 2/27
👍️0
Trooperstocks Trooperstocks 10 월 전
$MDAI News: Spectral AI Appoints Dr. J. Michael DiMaio to Board of Directors
Spectral AI, Inc.
Mon, Feb 12, 2024, 8:00 AM EST

In This Article:
MDAI
+2.28%
MDAIW
Spectral AI, Inc.

The Company’s two largest stockholders holding approximately 45% of the Company’s outstanding shares have extended their lock-up agreements for an additional 180 days

DALLAS, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on the unmet need for improved medical diagnostics to allow faster and more accurate treatment decisions in wound care, today announces the appointment of Dr. J. Michael DiMaio to its Board of Directors, effective February 7, 2024. Dr. DiMaio joins the Board as a non-executive member to fill the vacancy left by the departure of Mr. Michael Murphy.

Dr. Michael DiMaio is one of the Company’s founders and previously served as the Company’s Chief Executive Officer and Chairman of the Board of Directors from 2011 to 2020. In 2020, he exited his positions with the Company and amicably resolved a dispute that had arisen at that time. He is the Chief of Staff and a practicing board-certified general, cardiac and thoracic surgeon at Baylor Scott & White-The Heart Hospitals, one of the busiest cardiovascular programs in the United States. Currently the hospitals that he oversees are rated with the highest quality scores by the Society of Thoracic Surgeons, Society of Vascular Surgery, and the American College of Cardiology. He supervises more than 650 physicians across six facilities that perform approximately 25,000 cardiovascular procedures annually.

Dr. DiMaio earned his medical degree from the University of Miami and completed his internal medicine, general surgery, and cardiothoracic surgery residencies at Duke University Medical Center and performed research under an NIH-sponsored grant. He has been elected or served as a member on many distinguished medical organizations including the American Surgical Association, Society of Thoracic Surgeons, American College of Surgeons, American Association of Thoracic Surgery, American Heart Association, American Burn Association, International Society of Heart and Lung Transplantation, American Society of Transplant Surgeons, and the Southern Thoracic Surgical Association.

He has authored nearly 500 peer-reviewed publications and abstracts, and directs a research group that has produced over 1000 publications in medical journals that include JAMA, New England Journal of Medicine, Lancet, Science, and Circulation. Dr. Michael DiMaio has served as an editorial board member or reviewer for some the most prestigious medical journals in the world and has served as a grant reviewer for the National Institutes of Health (NIH), the American Heart Association, and the U.S. Department of Defense in an addition to serving on international medical guideline committees.

In clinical trials, he has been the principal investigator for numerous medical drugs and devices that have received FDA approval and commercialization. He has been awarded over $150 million funding from the NIH, the American Heart Association, the National Science Foundation, the U.S. Department of Defense, the Department of Health and Human Services, and the Biomedical Advanced Research Development Authority (BARDA). Currently, he oversees more than 120 clinical trials at the Baylor Scott & White Research Institute and serves as Chairman of the Cardiovascular Research Review Committee for the health care system.

"I am pleased to welcome back Dr. Michael DiMaio to Spectral AI’s Board of Directors," said Richard Cotton, Chairman of the Board of Directors. "Dr. DiMaio’s deep knowledge and application of innovative medical device technologies, decades of direct patient care, and experiences within some of the United States’ preeminent medical systems and current leadership make him uniquely qualified to support the planned commercialization and ongoing development of our DeepView™ System.”

"I have spent a great deal of my career developing technologies that improve patient outcomes while delivering tangible value across the healthcare spectrum and founded this company with the intent to fill the unmet clinical need for a decision-assist device to improve wound care management,” said Dr. DiMaio. “I believe that the Company’s AI-driven wound imaging and assessment technology platform is poised to deliver on those objectives, and I am very pleased to be in a position to help advance this exciting technology towards commercialization of current and future indication developments.”

The Company also announced that Dr. DiMaio and Erich Spangenberg, who together hold approximately 45% of the Company’s outstanding shares, have each agreed to an additional six-month extension of the current lock-up of their outstanding shares pursuant to the Registration Rights/Lock-Up Agreement entered into by each of them in connection with the Company’s business combination transaction in September 2023.

About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView® System. DeepView® is a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of substantially exceeding the current standard of care in the future, DeepView® is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about DeepView®, visit www.spectral-ai.com.

Forward Looking Statements

Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.

These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.

Investors should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.

Contacts




Investors



Equity Group



Devin Sullivan

Conor Rodriguez

Managing Director

Analyst

dsullivan@equityny.com

crodriguez@equityny.com


Media



Russo Partners



David Schull



(858) 717-2310



david.schull@russopartnersllc.com
👍️ 2 💪 1 💯 1
Trooperstocks Trooperstocks 10 월 전
$MDAI #ArtificalIntelligence #AI sector growth - Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment in wound care. http://spectral-ai.com $JNJ $LLY
👍️0
Trooperstocks Trooperstocks 10 월 전
$MDAI #Nasdaq NEWS - Spectral AI to Participate in the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference https://www.wsj.com/articles/spectral-ai-to-participate-in-the-2024-btig-medtech-digital-health-life-science-diagnostic-tools-conference-173ac0ec?reflink=mw_share_twitter
#BreakingNEWS #Nasdaq #2024Conference
👍️0
Trooperstocks Trooperstocks 10 월 전
$MDAI Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment in wound care. http://spectral-ai.com
👍️ 2 💪 1
Trooperstocks Trooperstocks 10 월 전
$MDAI Making a nice move $2.28 +11.22% HOD $2.3199 in jeopardy.
👍️ 1 💪 1
williams45 williams45 10 월 전
With a 52-week range from 1.7900 to 19.5000, $MDAI showcases its resilience and growth trajectory, capturing the attention of investors
https://investors.spectral-ai.com/news-releases/news-release-details/spectral-ai-announces-publication-letter-shareholders
👍️0
Trooperstocks Trooperstocks 10 월 전
Good morning $MDAI Premarket numbers $2.19 + 6.83%
👍️ 1 💪 1
scottyb scottyb 10 월 전
and so what
👍️0
Trooperstocks Trooperstocks 10 월 전
$MDAI On watch closely after hours and pre-market.
👍️ 1 😍 1
Trooperstocks Trooperstocks 10 월 전
$MDAI Nice close $2.05 +5.67% HOD $2.12 RSI Curling Upwards.
👍️ 2 💯 1

최근 히스토리

Delayed Upgrade Clock